Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Cystic Fibrosis
Interventions
DRUG

Sodium 4-Phenylbutyrate (4PBA)

The standard oral adult dose is 20g/day (tablets) for 4 days.

DRUG

Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)

Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.

DRUG

Placebo

The placebo dose will match the oral tablets in arm 1, maintaining the study blind.

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Children's Hospital of Philadelphia

OTHER

NCT00016744 - Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis) | Biotech Hunter | Biotech Hunter